News
Select year:
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Click here for announcements regarding managers transactions.
Click here for news in Danish.
December 16, 2024 | Press Releases
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India December 13, 2024 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic December 11, 2024 | Company Announcements
Bavarian Nordic to Launch DKK 150 Million Share Buy-back ProgramNovember 29, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 15, 2024 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024October 29, 2024 | Press Releases
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine September 26, 2024 | Company Announcements
Bavarian Nordic Upgrades its Financial Guidance for 2024September 26, 2024 | Company Announcements
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines September 24, 2024 | Company Announcements
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines September 19, 2024 | Press Releases
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for AdolescentsSeptember 18, 2024 | Company Announcements
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for AfricaSeptember 13, 2024 | Company Announcements
Bavarian Nordic Receives WHO Prequalification for Mpox VaccineSeptember 12, 2024 | Press Releases
Bavarian Nordic Provides Update on the Mpox Vaccine Supply SituationSeptember 05, 2024 | Press Releases
First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of CongoSeptember 05, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseAugust 27, 2024 | Press Releases
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in SingaporeAugust 22, 2024 | Company Announcements
Bavarian Nordic Announces First Half 2024 ResultsAugust 21, 2024 | Company Announcements
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European CountryAugust 17, 2024 | Press Releases
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global StakeholdersAugust 16, 2024 | Press Releases
Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to AdolescentsAugust 13, 2024 | Company Announcements
Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in AfricaAugust 13, 2024 | Company Announcements
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine August 08, 2024 | Company Announcements
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine ProductionJuly 26, 2024 | Press Releases
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox VaccineJuly 18, 2024 | Company Announcements
Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine